Jin Seok Kim

机构：Yonsei University, Severance Hospital, University of Ulsan, Yonsei University Health System · ORCID：0000-0001-8986-8436

发表论文 778 篇 · 总被引 13049 次 · h-index 54

代表论文

• Management of Atypical Haemolytic Uraemic Syndrome With Triggers: Diagnostic and Treatment Algorithms From an Asia‐Pacific Perspective (2025 · Nephrology · 被引 5)
• Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial (2025 · The Lancet Haematology · 被引 4)
• Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies (2025 · Blood · 被引 2)
• Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003) (2025 · Blood Cancer Journal · 被引 2)
• Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial (2026 · Journal of Clinical Oncology · 被引 1)
• Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL) (2025 · Blood · 被引 1)